Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metamark Genetics has collaborated with Definiens in which it will combine its proprietary multiplex detection platform with Definiens image analysis technology to produce prognostic and predictive assays for early-stage cancers.
Subscribe to our email newsletter
Metamark’s quantitative diagnostic approach detects and account for small regions of molecular cancer cells within an otherwise indolent tumor.
Metamark has also developed prognostic and predictive assays portfolio with has the ability to address the heterogeneous nature of tumors not only between one patient and the next, but also within an individual patient’s tumor.
Definiens Sales & Operations vice president Thomas Colarusso said they believe the Definiens Developer XD and Tissue Studio software will facilitate Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays.